You are here

Article Text

Article menu

Download PDFPDF

Vaginal and vulvar cancer
2022-RA-642-ESGO Long term follow-up in patients treated with electrochemotherapy for vulvar cancer
Free
  1. Anna Myriam Perrone1,2,
  2. Giacomo Corrado3,4,
  3. Giorgia Garganese4,5,
  4. Camelia Alexandra Coada2,
  5. Martina Ferioli1,2,
  6. Eugenia de Crescenzo1,2,
  7. Marco Tesei1,2,
  8. Giulia Dondi1,2,
  9. Luca Tagliaferri3,4,
  10. Marco Di Stanislao1,2,
  11. Simona Maria Fragomeni3,4,
  12. Francesca de Terlizzi6,
  13. Alessio G Morganti1,2,
  14. Giovanni Scambia3,4 and
  15. Pierandrea de Iaco1,2
  1. 1IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy
  2. 2University of Bologna, Bologna, Italy
  3. 3Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
  4. 4Università Cattolica del Sacro Cuore, Rome, Italy
  5. 5Gynecology and Breast Care Center, Mater Olbia Hospital, Olbia, Italy
  6. 6IGEA S.p.A, Carpi, Italy

Abstract

Introduction/Background Recurrence of vulvar cancer (VC) poses management problems due to the advanced age and comorbidities of the patients. Electrochemotherapy (ECT) with bleomycin is a new treatment option for these cases. We previously evaluated the ECT short-term response of recurrent VCs refractory to standard therapies. To date, no long-term follow-up results are available in such patients. This is a multicenter observational study carried out in two Italian centers with the purpose of evaluating the two-year outcomes of these patients.

Methodology Data about patients, tumor characteristics, ECT cycles, clinical response and follow-up were recorded. The procedures were performed according to European Standard Operative Procedure (ESOPE) guidelines. Response was evaluated according to the RECIST criteria.

Results Fifty-one patients, with a median age of 81.1±7.9 years and affected by squamous cellular carcinoma were treated with ECT. The majority of patients received one ECT with a range between 1–4 sessions. No serious adverse events were reported. A total of 20 patients had complete remission (CR) among which 32% retained their disease-free status after 2-years (median recurrence time of 16.8 months). Out of the 13 patients with initial partial response (PR), 30% did not show disease progression (median recurrence time of 15.4 months). On the other hand, patients with stable (SD) or progressive disease (PD) showed signs of worsening after 3.9 and 5.3 months, respectively (p=0.04). As far as survival is concerned, median survival was 18.8 months for patients with CR, 13.1 months for patients with PR, 6.7 and 11.1 months for patients with SD and PD respectively (p=0.002).

Abstract 2022-RA-642-ESGO Figure 1
Abstract 2022-RA-642-ESGO Figure 1

A) Progression free survival (PFS) and B) Overall survival of patients treated with ECT for recurrent vulvar sequamous cellular carcinoma

Conclusion Long follow-up of VC patients has showed that those who benefit most from ECT treatment were complete responders. Based on these results and considering the scarce availability of treatment options for VC recurrences, ECT represents a promising alternative of these patients.

https://doi.org/10.1136/ijgc-2022-ESGO.923

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.